Alley SC, Okeley NM and Senter PD, ‘Antibody–Drug Conjugates: Targeted Drug Delivery for Cancer’ (2010) 14 Current Opinion in Chemical Biology 529
Baurin N and others, ‘Design and Characterization of Libraries of Molecular Fragments for Use in NMR Screening against Protein Targets’ (2004) 44 Journal of Chemical Information and Modeling 2157 <https://contentstore.cla.co.uk/secure/link?id=e3feb169-e40b-f011-90cc-c5989c4ef87d>
Beck A and others, ‘Strategies and Challenges for the next Generation of Therapeutic Antibodies’ (2010) 10 Nature Reviews Immunology 345
Bissantz C, Kuhn B and Stahl M, ‘A Medicinal Chemist’s Guide to Molecular Interactions’ (2010) 53 Journal of Medicinal Chemistry 5061 <https://contentstore.cla.co.uk/secure/link?id=fb92e363-cb0b-f011-90cc-c5989c4ef87d>
Blake JF, ‘Identification and Evaluation of Molecular Properties Related to Preclinical Optimization and Clinical Fate’ (2005) 1 Medicinal Chemistry 649
Bradbury ARM and others, ‘Beyond Natural Antibodies: The Power of in Vitro Display Technologies’ (2011) 29 Nature Biotechnology 245
Brignier AC and Gewirtz AM, ‘Embryonic and Adult Stem Cell Therapy’ (2010) 125 Journal of Allergy and Clinical Immunology S336
Castanotto D and Rossi JJ, ‘The Promises and Pitfalls of RNA-Interference-Based Therapeutics’ (2009) 457 Nature 426
Chandra N, ‘Computational Systems Approach for Drug Target Discovery’ (2009) 4 Expert Opinion on Drug Discovery 1221
Colquhoun D, ‘Binding, Gating, Affinity and Efficacy: The Interpretation of Structure-Activity Relationships for Agonists and of the Effects of Mutating Receptors’ (1998) 125 British Journal of Pharmacology 923
Congreve M and others, ‘Recent Developments in Fragment-Based Drug Discovery’ (2008) 51 Journal of Medicinal Chemistry 3661 <https://contentstore.cla.co.uk/secure/link?id=0bbaf30c-e20b-f011-90cc-c5989c4ef87d>
Copeland, Robert Allen, Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists, vol Methods of biochemical analysis (J Wiley 2005) <https://onlinelibrary.wiley.com/doi/book/10.1002/9781118540398>
Cornish-Bowden, Athel, Fundamentals of Enzyme Kinetics (3rd ed, Portland 2004)
DiMasi JA, Hansen RW and Grabowski HG, ‘The Price of Innovation: New Estimates of Drug Development Costs’ (2003) 22 Journal of Health Economics 151
Ducry L and Stump B, ‘Antibody−drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies’ (2010) 21 Bioconjugate chemistry 5
Dunlop J, ‘High-Throughput Electrophysiology: An Emerging Paradigm for Ion-Channel Screening and Physiology’ (2008) 7 Nature Reviews Drug Discovery 358
Engel, Thomas and Gasteiger, J., Chemoinformatics: A Textbook (2003)
Fitt R and Nodder E, ‘Setting the Threshold for Industrial Application: The UK Diverges from Europe’ (2010) 5 Journal of Intellectual Property Law & Practice 560
Gasteiger, J., Handbook of Chemoinformatics: From Data to Knowledge (2003) <https://onlinelibrary.wiley.com/doi/book/10.1002/9783527618279>
Gibb, Alasdair J., Foreman, John C., and Johansen, Torben, Textbook of Receptor Pharmacology (3rd ed, CRC Press 2011)
Grimm D, ‘Small Silencing RNAs: State-of-the-Art’ (2009) 61 Advanced Drug Delivery Reviews 672
Gu, Jenny and Bourne, Philip E., Structural Bioinformatics, vol Methods of biochemical analysis (2nd ed, Wiley 2008)
Holliger P and Hudson PJ, ‘Engineered Antibody Fragments and the Rise of Single Domains’ (2005) 23 Nature Biotechnology 1126
Hopkins AL and Groom CR, ‘Opinion: The Druggable Genome’ (2002) 1 Nature Reviews Drug Discovery 727
Hopkins AL, Groom CR and Alex A, ‘Ligand Efficiency: A Useful Metric for Lead Selection’ (2004) 9 Drug Discovery Today 430
‘Human Embryonic Stem Cells: Derivation, Culture, and Differentiation: A Review’
Ikura M and Inouye M, ‘NMR Structure of the Histidine Kinase Domain of the : E. Coli: Osmosensor EnvZ : Article : Nature’ (1998) 396 Nature 88
Jarnagin K, Receptor Binding in Drug Discovery (John Wiley & Sons, Ltd 2001)
——, ‘Receptor Binding in Drug Discovery’, eLS
Jinek M and Doudna JA, ‘A Three-Dimensional View of the Molecular Machinery of RNA Interference’ (2009) 457 Nature 405
Kalluri R and Kanasaki K, ‘RNA Interference: Generic Block on Angiogenesis’ (2008) 452 Nature 543
Kenakin TP, ‘Cellular Assays as Portals to Seven-Transmembrane Receptor-Based Drug Discovery’ (2009) 8 Nature Reviews Drug Discovery 617
Khawaja X, Dunlop J and Kowal D, ‘Scintillation Proximity Assay in Lead Discovery’ (2008) 3 Expert Opinion on Drug Discovery 1267
Kola I and Landis J, ‘Opinion: Can the Pharmaceutical Industry Reduce Attrition Rates?’ (2004) 3 Nature Reviews Drug Discovery 711
Krohn KA and Link JM, ‘Interpreting Enzyme and Receptor Kinetics: Keeping It Simple, but Not Too Simple’ (2003) 30 Nuclear Medicine and Biology 819
Leach, Andrew R. and Gillet, Valerie J., An Introduction to Chemoinformatics (2003)
Lipinski CA and others, ‘Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings’ (1997) 23 Advanced Drug Delivery Reviews 3
Lledo P-M, Merkle FT and Alvarez-Buylla A, ‘Origin and Function of Olfactory Bulb Interneuron Diversity’ (2008) 31 Trends in Neurosciences 392
Macarron R and others, ‘Impact of High-Throughput Screening in Biomedical Research’ (2011) 10 Nature Reviews Drug Discovery 188
Matter H, ‘Selecting Optimally Diverse Compounds from Structure Databases: A Validation Study of Two-Dimensional and Three-Dimensional Molecular Descriptors’ (1997) 40 Journal of Medicinal Chemistry 1219 <https://contentstore.cla.co.uk/secure/link?id=c491b572-220b-f011-90cc-c5989c4ef87d>
Murray CW, ‘Fragment-Based Drug Discovery Applied to Hsp90. Discovery of Two Lead Series with High Ligand Efficiency’ (2010) 53 Journal of Medicinal Chemistry 5942
Murray CW and Rees DC, ‘The Rise of Fragment-Based Drug Discovery’ (2009) 1 Nature Chemistry 187
Nagorsen D and Baeuerle PA, ‘Immunomodulatory Therapy of Cancer with T Cell-Engaging BiTE Antibody Blinatumomab’ (2011) 317 Experimental Cell Research 1255
Nelson, David L., Cox, Michael M., and Lehninger, Albert L., Lehninger Principles of Biochemistry (5th ed, WH Freeman 2008)
Orengo, Christine Ann, Thornton, Janet M., and Jones, David Tudor, Bioinformatics: Genes, Proteins and Computers (BIOS 2003) <http://www.vlebooks.com/vleweb/product/openreader?id=UCL&isbn=9780203427828>
Overington JP, Al-Lazikani B and Hopkins AL, ‘How Many Drug Targets Are There?’ (2006) 5 Nature Reviews Drug Discovery 993
Patrick, Graham L., An Introduction to Medicinal Chemistry (2017)
Petsko, Gregory A. and Ringe, Dagmar, Protein Structure and Function, vol Primers in biology (New Science 2004)
Pillay V, Gan HK and Scott AM, ‘Antibodies in Oncology’ (2011) 28 New Biotechnology 518
Rang, H. P. and Dale, M. Maureen, Pharmacology (9th ed, Churchill Livingstone 2019) <https://elsevierelibrary.co.uk/product/9780702074462>
Richard M. Durbin, ‘A Map of Human Genome Variation from Population-Scale Sequencing’ (2010) 467 Nature 1061
Schrama D, Reisfeld RA and Becker JC, ‘Antibody Targeted Drugs as Cancer Therapeutics’ (2006) 5 Nature Reviews Drug Discovery 147
Selzer, P. M., Rohwer, A., and Marhöfer, R. J., Applied Bioinformatics: An Introduction (Springer 2008)
Shen J and others, ‘Suppression of Ocular Neovascularization with siRNA Targeting VEGF Receptor 1’ (2005) 13 Gene Therapy 225
Smith RA, ‘Discovery of Heterocyclic Ureas as a New Class of Raf Kinase Inhibitors: Identification of a Second Generation Lead by a Combinatorial Chemistry Approach’ (2001) 11 Bioorganic & Medicinal Chemistry Letters 2775
Stadtfeld M and Hochedlinger K, ‘Induced Pluripotency: History, Mechanisms, and Applications’ (2010) 24 Genes & Development 2239
Swinney DC and Anthony J, ‘How Were New Medicines Discovered?’ (2011) 10 Nature Reviews Drug Discovery 507
Thomas, Gareth, Fundamentals of Medicinal Chemistry (2003)
Vaishnaw AK and others, ‘A Status Report on RNAi Therapeutics’ (2010) 1 Silence
Veber DF and others, ‘Molecular Properties That Influence the Oral Bioavailability of Drug Candidates’ (2002) 45 Journal of Medicinal Chemistry 2615 <https://contentstore.cla.co.uk/secure/link?id=de13eed7-c90b-f011-90cc-c5989c4ef87d>
Watt FM and Driskell RR, ‘The Therapeutic Potential of Stem Cells’ (2010) 365 Philosophical Transactions of the Royal Society B: Biological Sciences 155
Webb S, ‘Pharma Interest Surges in Antibody Drug Conjugates’ (2011) 29 Nature Biotechnology 297
Weiner LM, Surana R and Wang S, ‘Monoclonal Antibodies: Versatile Platforms for Cancer Immunotherapy’ (2010) 10 Nature Reviews Immunology 317
Welsch ME, Snyder SA and Stockwell BR, ‘Privileged Scaffolds for Library Design and Drug Discovery’ (2010) 14 Current Opinion in Chemical Biology 347
Wilhelm S, ‘Discovery and Development of Sorafenib: A Multikinase Inhibitor for Treating Cancer’ (2006) 5 Nature Reviews Drug Discovery 835
Willett P, Barnard JM and Downs GM, ‘Chemical Similarity Searching’ (1998) 38 Journal of Chemical Information and Modeling 983 <https://contentstore.cla.co.uk/secure/link?id=e44202ff-cd0b-f011-90cc-c5989c4ef87d>
Woodhead AJ, ‘Discovery of (2,4-Dihydroxy-5-Isopropylphenyl)-[5-(4-Methylpiperazin-1-Ylmethyl)-1,3-Dihydroisoindol-2-Yl]Methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design’ (2010) 53 Journal of Medicinal Chemistry 5956 <https://contentstore.cla.co.uk/secure/link?id=2cf7cd66-e30b-f011-90cc-c5989c4ef87d>
Xiong, Jin, Essential Bioinformatics (Cambridge University Press 2006)
Zvelebil, Marketa J. and Baum, Jeremy O., Understanding Bioinformatics (Garland Science 2008) <https://bibliu.com/app/#/view/books/9781136976964/pdf2htmlex/index.html#page_Cover>
